Gilead soars 11% after reporting positive news on potential coronavirus treatment

• $4$4 said that remdesivir, its leading coronavirus treatment, succeeded in a critical trial.
• Shares surged as much as 11% on the news, and led US stocks higher in premarket trading.
• $4
• $4

Shares of $4 surged as much as 11% in early trading Wednesday after $4 a $4.

The positive news led the S&P 500 as much as 2.4% higher in premarket trading in New York.

Gilead's remdesivir, an antiviral drug, is currently being tested in several ongoing trials with COVID-19 patients. Wednesday, Gilead $4 "positive data."

The study is being run by the US National Institutes of Health. Gilead did not provide any further data on remdesivir, but said that it understands that the trial has met its primary endpoint $4.

Gilead said that the National Institute of Allergy and Infectious Diseases at the NIH will provide further information at a briefing.

Read more: $4

Shares of Gilead have gained as much as $4, on hopes that remdesivir would prove to be an effective treatment for COVID-19.

The antiviral drug has not been approved to treat any diseases, but was given to Ebola patients in the past. It's the leading hope for a coronavirus treatment, as other drugs have disappointed in early study results.